The Inhibitory Role of $\alpha2,6$-Sialylation in Adipogenesis*

Received for publication, July 10, 2016, and in revised form, December 17, 2016 Published, JBC Papers in Press, December 28, 2016, DOI 10.1074/jbc.M116.747667

Tomoko Kaburagi†§1, Yasuhiko Kizuka§, Shinobu Kitazume§, and Naoyuki Taniguchi§2

From the 1Department of Health Science, Faculty of Sports and Health Sciences, Daito Bunka University, Higashi-Matsuyama, Saitama 355-8681, Japan and the 2Disease Glycomics Team, Systems Glycobiology Research Group, RIKEN-Max Planck Joint Research Center for Systems Chemical Biology, Global Research Cluster, RIKEN, Wako, Saitama 351-0198, Japan

Edited by Gerald W. Hart

Adipose tissue plays critical roles in obesity and related diseases such as diabetes and cardiovascular diseases. Previous reports suggest that glycans, the most common posttranslational modifications, are involved in obesity-related diseases, but what type of glycan regulates adipogenesis during obesity remains unclear. In this study, we first quantified the mRNA levels of 167 genes (encoding 144 glycosyltransferases and 23 related enzymes) in visceral adipose tissues (VATS) from control mice and high-fat diet (HFD)-induced obese mice. We found that a gene encoding $\beta$-galactoside $\alpha2,6$-sialyltransferase-1 (St6gal1), a key enzyme responsible for the biosynthesis of $\alpha2,6$-linked sialic acid in N-linked glycans, was most down-regulated in VATs from obese mice. We confirmed the reduction in $\alpha2,6$-sialic acid in VATs from obese mice and differentiated adipocyte model 3T3-L1 cells. Using proteomic analysis, integrin-$\beta1$ was identified as one of the target $\alpha2,6$-sialylated proteins in adipose tissues, and phosphorylation of its downstream molecules focal adhesion kinase was found to be decreased after HFD feeding. St6gal1 overexpression in differentiating 3T3-L1 cells inhibited adipogenesis with increased phosphorylation of focal adhesion kinase. Furthermore, St6gal1 knockout mice exhibited increased bodyweight and VAT weight after HFD feeding. The down-regulation of St6gal1 during adipogenesis was canceled by treatment with a DNA methyltransferase inhibitor, suggesting an involvement of epigenetic DNA methylation in St6gal1 silencing. Our findings suggest that St6gal1 has an inhibitory role in adipogenesis through integrin-$\beta1$ activation, providing new insights into the roles and regulation mechanisms of glycans in adipocytes during obesity.

Currently, adipose tissue is recognized as an endocrine organ that controls metabolism-related diseases (1, 2). Adipokines, which are bioactive molecules secreted from adipose tissue, are involved in energy metabolism, vascular homeostasis, and the immune response (1–5). Obesity results from excess accumulation of adipose tissue with hypertrophy and hyperplasia of adipocytes (5–9), which leads to abnormal secretion of adipocytokines (6, 7) and triggers various diseases, including diabetes and cardiovascular diseases (2, 6, 7, 10). Although these morphofunctional modifications of adipocyte are related to cell adhesion molecules, such as integrins (11, 12), the precise molecular mechanisms behind the adipocyte growth (referred to as adipogenesis) in obesity are not fully understood.

Glycosylation is the most common posttranslational modification of proteins and confers both structural and functional diversity to proteins (13, 14). The biosynthesis of glycans is catalyzed by glycosyltransferases, and ∼200 glycosyltransferases have been cloned in mammals (13, 15, 16). The development of various diseases, including diabetes, cardiovascular diseases, and emphysema, is regulated by glycosylation via the action of glycosyltransferases (17–22). Considering that these disorders are closely related to obesity, their product glycans are also assumed to be involved in the dysfunction of adipose tissue by obesity.

There are now some reports showing that obesity functionally changes the expression of glycans in adipose tissues. Ganglioside GM3 is up-regulated in adipose tissue by obesity, which leads to insulin resistance (19, 20). It is also reported that, in the 3T3-L1 adipocyte cell model, O-GlcNAcylation and N-glycosylation are involved in adipogenesis or adipocyte differentiation and insulin-induced uptake of glucose (23–26). These findings strongly suggest that glycosylation in adipose tissue is also key to understanding the molecular mechanisms underlying obesity and related diseases. However, it is not fully understood which glycans are functionally involved in adipogenesis during obesity.

In this study, we used a mouse model of high fat diet (HFD)-induced obesity and adipocyte model 3T3-L1 cells to identify glycosyltransferase genes whose expression was altered in visceral adipose tissues (VATs) during obesity. We found that $\beta$-galactoside $\alpha2,6$-sialyltransferase-1 (ST6GAL1), a key enzyme responsible for the formation of the Sia$\alpha2,6$-Gal linkage in N-linked glycans, was the most down-regulated glycosyltransferase in VATs from obese mice compared with control mice.

* This work was supported by RIKEN (the Systems Glycobiology Research Project) (to N. T.) and by Japan Society for the Promotion of Science Grant-in-Aid for Challenging Exploratory Research 15K14481 (to N. T.), Grant-in-Aid for Scientific Research (B) 15H04700 (to N. T.), and Grant-in-Aid for Scientific Research (C) 15K00885 (to T. K.). The authors declare that they have no conflicts of interest with the contents of this article.

† To whom correspondence may be addressed: Dept. of Health Science, Faculty of Sports and Health Sciences, Daito Bunka University, 560 Iwadono, Higashi-Matsuyama, Saitama, Japan. Tel.: 81-493-31-1558; Fax: 81-493-31-1562; E-mail: t.kabu@ic.daito.ac.jp.

‡ To whom correspondence may be addressed: Disease Glycomics Team, Systems Glycobiology Research Group, RIKEN-Max Planck Joint Research Center for Systems Chemical Biology, Global Research Cluster, RIKEN, 2-1 Hiro sawa, Wako, Saitama, Japan. Tel.: 81-48-467-9616; Fax: 81-48-467-9617; E-mail: dglycotani@riken.jp.

§ This article contains supplemental Figs. 1–4.

§2 The abbreviations used are: HFD, high-fat diet; VAT, visceral adipose tissue; CON, control; SSA, Sambucus sieboldiana agglutinin; FAK, focal adhesion kinase; 5-AZA, 5-aza-2′-deoxycytidinedeoxycytidinedeoxycytidinedeoxycytidine; C/EBP, CCAAT enhancer-binding protein.
Results

St6gal1 is the Most Down-regulated Glycosyltransferase Gene in VATs of Obese Mice—To investigate how glycosylation is involved in obesity, we first designed experiments using HFD-fed obese mice. HFDs induce obesity in mice with dysregulated metabolism of glucose and lipid as well as disturbed production of adipocytokines (4, 9, 27, 28). We confirmed that body weights were heavier in our HFD mice than in CON mice after 8 weeks on the experimental diets (Fig. 1A). We then quantified the mRNA levels of 167 genes (encoding 144 glycosyltransferases and related enzymes) in VATs from CON mice (with expression lev-

Suppression of Adipogenesis by α2,6-Sialylation

other mouse tissues (brain, liver, testis, and kidney) for comparison (29), VAT expresses a unique set of glycan-related genes. For example, the VAT shows high levels of B3galT2 and undetectable levels of B3gnt2 and A3galt2, which are highly expressed in other tissues (supplemental Figs. 1–3) (29), demonstrating tissue-specific regulation of glycan expression. Compared with VATs from CON mice, limited numbers of genes were found to be up-regulated in VATs from HFD mice (supplemental Figs. 1 and 2). However, more strikingly, several genes were dramatically down-regulated in VATs from HFD mice (Fig. 1B and supplemental Figs. 1 and 2). St6gal1 was the most down-regulated gene, reduced to less than 4% of CON levels, suggesting that St6gal1 has roles in visceral adipogenesis. We further confirmed a reduction in the amount of ST6gal1 products (namely, α2,6-sialic acid) in mouse VATs by both lectin blotting (Fig. 1C) and histochemical staining (Fig. 1D), with Sambucus sieboldiana agglutinin (SSA) lectin, which specifically recognizes α2,6-sialylated glycoconjugates (30). The morphology of adipocytes with large lipid droplets and its hypertrophic change by HFD feeding are consistent with previous reports (31, 32).

Integrin-β1 Was Identified as an α2,6-Sialylated Protein in Mouse VATs by Mass Spectrometry—To elucidate the mechanisms by which St6gal1-mediated sialylation is involved in obesity, we set out to identify the target protein functionally modified by ST6gal1 in adipose tissues. We biochemically purified the α2,6-sialylated proteins in VATs using SSA lectin. As shown in Fig. 2A, of several proteins with reduced reactivity to SSA, a protein of 120–130 kDa showed a clear reduction in SSA reactivity under HFD feeding (arrow), whereas many other proteins showed no changes. A reduction in SSA reactivity of the 120- to 130-kDa protein was also observed with lectin blotting, as shown in Fig. 1C. We excised this 120- to 130-kDa band and, using MS analysis, identified six candidate proteins to be included (Fig. 2B and supplemental Fig. 4). We focused on integrin-β1 because its molecular weight was consistent with the band, and previous studies report that integrins are involved in adipocyte differentiation (33–35). We found that α2,6-sialylation of integrin-β1 in mouse VATs was significantly reduced in HFD mice compared with CON mice (Fig. 2C). The loss of SSA reactivity of integrin-β1 from St6gal1 knockout VATs confirmed the specificity of this lectin. To examine the role of α2,6-sialylation on integrin-β1 in adipose tissue, we analyzed phosphorylation of focal adhesion kinase (FAK). FAK is the major downstream regulator of integrin-β1 and is activated by phosphorylation upon binding of integrin-β1 to extracellular matrix proteins such as fibronectin (36, 37). We observed a significant decrease in the phosphorylation levels of FAK in VATs of HFD mice compared with CON mice (Fig. 2D). These results indicate that the functions of integrin-β1 in VATs are disturbed during the induction of obesity by HFD feeding, concomitant with the decrease in its α2,6-sialylation.

Down-regulation of St6gal1 in Differentiated 3T3-L1 Adipocytes—Next, using 3T3-L1 cells as a mouse preadipocyte model, we asked whether the expression of St6gal1 is also down-regulated during adipocyte differentiation. For differentiation, 3T3-L1 cells were treated with dexamethasone,
Suppression of Adipogenesis by α2,6-Sialylation

3-isobutyl-1-methylxanthine, and insulin for 2 days, followed by insulin for 12 days according to an established method (38, 39) (Fig. 3A, top panel). We successfully induced adipocyte differentiation using these cells. This was evidenced by an increased number and enlargement of lipid droplets (Fig. 3A, bottom panel) and the induction of several key marker genes, including adiponectin (Adipoq), peroxisome proliferator-activated receptor γ (Pparg), and fatty acid binding protein 4 (Fabp4) (Fig. 3B). In contrast, the expression level of St6gal1 was significantly reduced during adipocyte differentiation (Fig. 3B), consistent with its down-regulation in the VATs of HFD mice described above.

To explore the transcriptional mechanism underlying the down-regulation of St6gal1, we focused on DNA methylation, as adipogenesis is regulated by epigenetic DNA methylation (40, 41). As expected, methylation-specific PCR using the 3T3-L1 genome revealed that methylation in a CpG island of the St6gal1 promoter was enhanced during adipogenesis (Fig. 3C). This suggests that epigenetic DNA hypermethylation is involved in the down-regulation of St6gal1 expression during adipogenesis. Consistent with this, treatment with a DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine (5-AZA) canceled the down-regulation of St6gal1 during adipocyte differentiation (Fig. 3D). Considering its down-regulation in both the VATs from HFD mice and 3T3-L1 adipocytes, we hypothesized that ST6GAL1 plays an inhibitory role in adipogenesis.

Overexpression of St6gal1 Inhibited Adipogenesis and Activated Integrin-β1 Signaling—To directly examine whether St6gal1 expression inhibits adipogenesis, St6gal1 was overexpressed in 3T3-L1 cells using an adenoviral vector (Fig. 4A). As a result, lipid accumulation (as assessed by oil red O staining) was clearly inhibited by overexpression of St6gal1 (Fig. 4A, bottom panel). Unexpectedly, however, the markers of adipogenesis showed only a slight decrease in expression with St6gal1 overexpression (Fig. 4B). Adipocyte differentiation generally involves several distinct phases, including proliferation and subsequent growth arrest of preadipocytes as the initial stage, followed by mitotic clonal expansion and terminal differentiation (38, 39). Overexpression of St6gal1 significantly suppressed preadipocyte proliferation, particularly at the early stage (Fig. 4C). Our results suggest that α2,6-sialylation inhibits the early stage of preadipocyte proliferation.

We identified integrin-β1 as a target protein of ST6GAL1 in adipose tissue (Fig. 2) and confirmed that St6gal1 overexpression increased α2,6-sialylation of integrin-β1 in this cell model (Fig. 4D). Integrin-β1 regulates adipocyte differentiation through the downstream activator FAK (34, 36, 42). We found that phosphorylation of FAK was increased by St6gal1 overexpression in differentiating 3T3-L1 cells (Fig. 4E). In addition, the effects of St6gal1 overexpression on Cebpb expression were attenuated by knocking down integrin-β1 (Fig. 4, F and G), supporting the notion that α2,6-sialylation of integrin-β1 regulates adipogenesis. Collectively, these results suggest that sustained α2,6-sialylation of integrin-β1 suppresses adipogenesis, probably by inhibiting preadipocyte proliferation.

HFD-fed St6gal1 Knockout Mice Gained More Body Weight and VAT Weight—Finally, we analyzed St6gal1 knockout mice to further investigate the in vivo role of ST6GAL1 in adipogenesis. After 8 weeks of HFD feeding, although no significant differences were observed in serum biomarkers (Fig. 5A), St6gal1 knockout mice gained more body weight and VAT weight than littermate heterozygous mice (Fig. 5, B and C). Intake of energy from the HFD in St6gal1 knockout mice (17.6 ± 1.0 kcal/mouse/day) was not significantly different from that of the heterozygous mice (15.3 ± 0.7 kcal/mouse/day). The expression level of a proliferation marker, Ki67 (43), was higher in VAT of St6gal1 knockout mice than in heterozygous mice (Fig. 6D), consistent with results from 3T3-L1 cells, where St6gal1 overexpression suppressed proliferation of adipocytes. These results indicate that dysregulated adipogenesis, but not excess food intake, in St6gal1 knockout mice leads to the increase in...
VAT weight, again suggesting that ST6GAL1 has a suppressive role in obesity.

**Discussion**

Here we have demonstrated for the first time that α2,6-sialylation inhibits adipogenesis, probably through functional modification of integrin-β1 (Fig. 6). A key glycosyltransferase gene, St6gal1, was down-regulated in adipose tissues from obese mice, probably by an epigenetic mechanism. Our results highlight the importance of glycosylation in obesity, which could lead to the development of a novel glycans-targeted strategy for the therapy of obesity-related diseases.

Integrin-β1 is functionally modified by ST6GAL1 (44–47). Previous reports have shown that integrin-β1 regulates various biological functions, including cell migration and signal transduction, and that these functions are partially mediated by its sialylation (44–48). St6gal1-null tumors showed a more differentiated phenotype and decreased FAK phosphorylation (49), indicating that ST6GAL1 alters cell properties through its modulation of integrin function, particularly in the context of cancer (50). Furthermore, the activity of integrin-β1 is proposed to be impaired during adipogenesis (12). Adipocyte differentiation is regulated by the downstream signaling of integrin-β1 such as FAK and ERK (34, 36, 42, 51). Consistent with these reports, our in vivo and in vitro results suggest that reduction of α2,6-sialylation of integrin-β1 is a key event for signaling in adipogenesis. Intriguingly, reduction in α2,6-sialylation seems to be protein-specific (Figs. 1C and 2A). Although sialylation of some proteins, including integrin-β1, was highly susceptible to St6gal1 down-regulation, other proteins retained their reactivity to SSA. Determining the mechanisms behind such protein selectivity on glycan alteration is crucial to understanding the detailed functions of glycosylation.

In general, adipogenesis consists of several distinct phases. Differentiation of 3T3-L1 cells into adipocytes also involves several steps (38, 39): an initial proliferation and subsequent growth arrest of preadipocytes, mitotic clonal expansion, and terminal differentiation. This process is regulated by several transcription factors, including peroxisome proliferator-activated receptor γ and CCAAT/enhancer binding proteins (C/EBPβ, C/EBPγ, and C/EBPa). This study shows that the initial preadipocyte proliferation, a prerequisite for subsequent differentiation (52), was inhibited by overexpression of St6gal1 (Fig. 4C). In addition, St6gal1 overexpression tended to reduce mRNA expression of the key transcription factors, especially Cebpb (Fig. 4B). Because previous reports indicate that C/EBPβ is required for mitotic clonal expansion (12, 53), ST6GAL1 might also inhibit the clonal expansion step. Although overexpression of St6gal1 greatly suppressed proliferation of preadipocytes (to approximately 50% of the control) (Fig. 4C), decreases in lipid accumulation (Fig. 4A) and the differentiation markers (Fig. 4B) were modest, suggesting that another unknown mechanism exists by which α2,6-sialylation is involved in regulation of adipogenesis. It should be noted that adipocyte differentiation involves multiple steps and that several glycoproteins were α2,6-sialylated in addition to integrin-β1 (e.g. cadherin-13) (Fig. 2, A and B). We showed that integrin-β1 is one of the functional targets of ST6GAL1 in adipocytes, but the functions of other α2,6-sialylated proteins in adipocytes will need to be determined in the future.

Our results showed that epigenetic DNA hypermethylation is involved in the down-regulation of St6gal1 expression during adipogenesis (Fig. 3, C and D). Although little is known about the epigenetic mechanisms governing glycosyltransferase expression (54–56), recent reports have revealed that DNA methylation in the CpG island of glycosyltransferase promoters is involved in their down-regulation, particularly under disease conditions (57). In terms of cancer biology, several mechanisms of epigenetic silencing of the St6gal1 gene have been reported, mediated by DNA methylation or microRNA (58–60). A more detailed analysis of the pathological regulation of the St6gal1 gene in adipocytes will be needed in the future.
St6gal1 knockout mice gained more body weight and VAT weight from HFD feeding than littermate heterozygous mice (Fig. 5, B and C) with increasing adipocyte proliferation (Fig. 5D), suggesting that adipogenesis is abnormally enhanced in these mutant mice. St6gal1 knockout mice have been reported to show multiple phenotypes involving abnormal B cell responses (61), altered T cell development in the thymus (62), and vulnerability of endothelial cells to apoptotic stimuli (63), but the effects of St6gal1 deficiency on adipogenesis have not yet been investigated. It was reported previously that SNPs at the St6gal1 gene are associated with obesity and type 2 diabetes (64, 65). These findings, together with our results, suggest that ST6GAL1 is involved not only in adipogenesis but also in the subsequent development of obesity and related disorders.

**Experimental Procedures**

**Materials**—The following antibodies were used: anti-integrin-β1 (610467) from BD Biosciences, anti-GAPDH (MAB374) and anti-FAK (06-534) from Millipore, anti-phospho-FAK (Tyr-397) (3283) from Cell Signaling Technology, anti-actin (A4700) from Sigma, and anti-ST6GAL1 from Immuno-Biological Laboratories (M2 rabbit polyclonal antibody) (66). Biotinylated SSA lectin was purchased from Seikagaku Corp. Primer-probe sets for mRNA quantification were purchased from Life Technologies: control Gapdh, 4308313; ribosomal RNA, 4308329; St6gal1, Mm00486119_m1; Adipoq, Mm00440940_m1; Pparg, Mm00445878_m1; Cebp, Mm00843434_s1; and Mki67, Mm01278617_m1.

**FIGURE 4. Overexpression of St6gal1 inhibited adipogenesis and enhanced integrin-β1 activity.** A, 3T3-L1 cells were infected with either an adenovirus vector encoding St6gal1 or a control vector (LacZ) before and during differentiation (days (d) 0 and 2), and were transfected with siRNA for Itgb1 before differentiation (day 0) (top panel). Microscopy images of oil red O staining of cells (bottom panel, left) were taken, and the amount of stained lipid in adipocytes was measured 7 days after differentiation (bottom panel, right). qPCR, quantitative PCR. B, on day 7, the levels of mRNA expression of adipogenesis-related genes were quantified (n = 3). C, 3T3-L1 cells (preadipocytes) were infected with St6gal1 or a control adenoviral vector (LacZ) on day 0. Cell proliferation was assessed at each time point after induction of differentiation (24 and 48 h) relative to the value of 0 h using the alamarBlue assay (n = 6). D, α2,6-sialylated proteins were pulled down with SSA lectin from 3T3-L1 lysates on day 7 and then subjected to SDS-PAGE and Western blot for integrin-β1. E, lysates of 3T3-L1 adipocytes on day 7 were blotted for FAK, phospho-FAK (p-FAK) and ST6GAL1 (left panel). The signal intensity of the bands in the Western blot was quantified and is shown as a graph (right panel). F, 3T3-L1 adipocytes were transfected with control siRNA or siRNA for Itgb1. Lysates of the cells on day 7 were blotted for integrin-β1 or actin. G, the levels of mRNA expression of adipogenesis-related genes were quantified on day 7 (n = 3). All graphs show mean ± S.E. (*, p < 0.05; **, p < 0.01; Student’s t test).
siRNAs were purchased from Qiagen: control siRNA, 1027280; mouse Itgb1, SI00194026.

**Animals and Diets**—Male C57BL/6J mice were obtained from Oriental Yeast (Tokyo, Japan). The generation of St6gal1-deficient mice has been described previously (61), from a C57BL/6 genetic background. C57BL/6J mice at 6 weeks of age were acclimated with a control diet based on AIN 93G (CON, containing 7% fat, D10012G, Research Diets Inc.) for 1 week. Then mice were fed with an HFD containing 56% fat supplemented with lard (D12052803, Research Diets Inc., n = 6) for 8 weeks to induce obesity or fed with a CON (n = 6). Littermates, St6gal1 homozygous (St6gal1+/−, n = 4), and heterozygous knockout mice (St6gal1+/−, n = 3), were given the CON diet for 4 weeks, followed by the HFD for 8 weeks. All mice were allowed free access to water and food. For the period of the study, body weight and food consumption were measured once a week. Prior to sacrifice, blood was collected under anesthesia, and VATs of the epididymis were collected, weighed, and frozen. All mice were housed (three or fewer mice per cage) at 23 ± 3°C and 55 ± 10% humidity. The light conditions were 14 h:10 h (lights on at 7 a.m.). The Animal Experiment Committee of RIKEN approved all animal experiments.

**Real-time PCR for a Large Set of Glycosyltransferase Genes**—Specific primers for 144 glycosyltransferase mRNAs and 23 mRNAs for related proteins were purchased from Qiagen in a 96-well-based form (67). Selected genes are listed in supplemental Figs. 1 and 2. Glycosyltransferases responsible for the early steps of N-glycan biosynthesis or glycosylphosphatidylinositol synthesis, such as the Alg genes, are not included in this list. Total RNA (1 μg) was reverse-transcribed using the RT2 First Strand Kit (Qiagen) in a 40-μl reaction mixture and then diluted with 182 μl of RNase-free water. The resultant cDNA solution was mixed with 2.7 μl of RT2 SYBR Green qPCR Mastermix (Qiagen) and 2.496 μl of water, and 25 μl of the mixture was applied to each well. cDNAs were amplified and analyzed using ABI Prism 7900HT (Applied Biosystems), in accordance with the RT2 Profiler PCR Array Handbook (Qiagen). The abundance of glycosyltransferase mRNA relative to that of housekeeping genes (average of Actb, B2m, Gapdh, and Hsp90ab1) was calculated using the ΔCt method.

**Protein Extraction from VATs**—Mouse VATs were homogenized with TBS containing 1% Triton X-100, a protease inhibitor mixture, and phosphatase inhibitors (Roche Applied Science). The insoluble debris and thick lipid layer were removed after centrifugation at 3000 × g for 5 min, and then the lysate

**Figure 5.** Male St6gal1 knockout mice gained more body weight and VAT weight from HFD feeding than littermate heterozygous mice. A, levels of serum biochemical markers after 8 weeks of HFD feeding. B, change in body weight of male mice fed a control diet for 4 weeks and subsequently fed an HFD for 8 weeks. C, weight of VATs after 8 weeks of HFD feeding. D, mRNA expression of the Ki67 gene in VATs. All graphs show mean ± S.E. (*, p < 0.05 versus St6gal1+/− by Mann-Whitney U test; #, p < 0.05 by Student’s t test).

**Figure 6.** Schematic of the inhibitory role of ST6GAL1 in adipogenesis. In the presence of ST6GAL1, adipogenesis is inhibited by α2,6-sialylation of integrin-β1 and by activation of downstream signaling, including FAK phosphorylation. During adipogenesis, St6gal1 expression is epigenetically silenced by DNA methylation, which leads to hyposialylation of integrin-β1, impairment of downstream signaling, and up-regulation of key adipogenic genes.
Suppression of Adipogenesis by α2,6-Sialylation

was sonicated for 5 s. Protein concentrations in tissue extracts and cells were measured using the BCA assay.

**Cell Culture, Viral Infection, and siRNA Transfection**—The culture procedure for 3T3-L1 cells is shown in brief in Fig. 3A. 3T3-L1 preadipocytes were cultured in DMEM supplemented with 10% FBS. 2 days post-confluence (day 0), cells were induced to differentiate in DMEM containing 10% FBS, 1 μg/ml insulin, 1 μM dexamethasone, and 0.5 mM 3-isobutyl-1-methyloxanthine. 2 days post-differentiation (day 2), the medium was replaced with DMEM containing 1 μg/ml insulin and 10% FBS. Over the next 12 days, the medium was replaced every other day with a new one (DMEM containing 1 μg/ml insulin and 10% FBS). A DNA methyltransferase inhibitor, 5-AZA, was added at 5 μM whenever the medium was replaced every other day. The adenosine infection and siRNA transfection procedures are shown in brief in Fig. 4A. An adenosine inhibitor designed to overexpress rat St6gal1 (63) or control vector (LacZ) was added to the culture medium twice (days 0 and 2). For knockdown of integrin-β1, cells on a 6-cm dish were transfected with 80 pmol of siRNA using 8 μl of Lipofectamine 2000 (Life Technologies) 2 days post-confluence (day 0). Seven days after differentiation (day 7), total RNA and whole cell lysates were collected. Cells were collected and lysed with TBS containing 1% Triton X-100, a protease inhibitor mixture, and phosphatase inhibitors (Roche Applied Science) and subjected to protein analysis.

**RNA Extraction, Reverse Transcription, and Real-time PCR**—Total RNA from cultured cells or mouse VATs was extracted using TRI Reagent (Molecular Research Center, Inc.) according to the protocol of the manufacturer. Total RNA (1 μg) was reverse-transcribed using Superscript III (Life Technologies). For real-time PCR, cDNA was mixed with TaqMan Universal PCR Master Mix (Life Technologies) and amplified using an ABI Prism 7900HT. mRNA levels were normalized to corresponding Gapdh or rRNA levels.

**Methylation-specific PCR Analysis**—Genomic DNA was extracted from differentiated (14 days) or undifferentiated (0 day) 3T3-L1 cells using a Mammalian Genomic DNA Miniprep Kit (Sigma) according to the instructions of the manufacturer. Bisulfite treatment was performed with an innuCONVERT Bisulfite Basic Kit (Analytijen). A genomic region in the CpG island of the St6gal1 promoter was amplified by PCR (Epitaq HS, Takara) using two primer sets designed for either methylated or unmethylated CpGs. The primers were as follows: methylated, 5′-CGTTAGGGTTGGGGAGGC-3′ (forward) and 5′-CCCCCTACCTCCTCTCCAAC-3′ (reverse); unmethylated, 5′-TGTTAGGGTTGGGGAGGTT-3′ (forward) and 5′-CCCCCTACCTCCTCTCCAAC-3′ (reverse).

**Cell Proliferation Assay**—3T3-L1 cells (preadipocytes) were infected with St6gal1 (n = 6) or control vector (LacZ, n = 6) on day 0, and cell proliferation was assayed at each time point (24 and 48 h) using alamarBlue (68). Briefly, 3T3-L1 cells were seeded at 1 × 10⁴ cells/well on a 96-well plate. After each incubation at 37 °C, a 1/10 volume of alamarBlue solution (Thermo Fisher Scientific) was directly added to the culture medium. After 3-h incubation at 37 °C, absorbance at 570 nm was measured. Values are shown relative to those of the cells on day 0.

**Western and Lectin Blots**—Proteins were separated by 5–20% gradient SDS-PAGE using the Laemmli buffer system and then transferred to nitrocellulose membranes. After blocking with 5% nonfat dry milk in TBS containing 0.05% Tween 20 (or blocking with TBS containing 0.1% Tween 20 for the blot), the membranes were incubated with primary antibodies or biotinylated lectin (diluted with the blocking buffer), followed by HRP-conjugated secondary antibodies or HRP-conjugated streptavidin (Vectastain ABC Standard Kit). Proteins were detected with Western Lightning ECL Pro (PerkinElmer Life Sciences) using an ImageQuant LAS-4000mini (GE Healthcare).

**SSA Lectin Precipitation**—Mouse VAT lysates (300 μg of protein in 500 μl of TBS containing 1% Triton X-100, a protease inhibitor mixture, and phosphatase inhibitors (Roche Applied Science)) were incubated with 30 μl of SSA-agarose (Honen Co.) for 16 h with gentle shaking at 4 °C. The precipitates were washed four times with PBS and then eluted by boiling with SDS sample buffer. The precipitated proteins were separated by SDS-PAGE, stained with silver or transferred to nitrocellulose, and then probed with an anti-integrin-β1.

**LC-MS/MS Analysis for Identification of Sialylated Proteins**—The gel band that was reduced in HFD VATs was precipitated with SSA lectin from CON VATs (120–130 kDa), excised, and cut into small pieces. After washing and destaining the gel pieces, cysteine residues were reduced by DTT and alkylated with iodoacetamide. Proteins were digested with modified trypsin, and the resulting peptides were subjected to LC/MS-MS. LC/MS-MS analysis was performed using an Advance Nano LC (Bruker-Michrom, Auburn, CA) and LTQ linear ion trap mass spectrometer (Thermo Fisher Scientific, Inc., San Jose, CA) equipped with a NANO HPLC capillary column C18 (0.075-mm inner diameter × 150-mm length, 3-μm particle size, Nikkyo Technos, Tokyo, Japan) using a linear gradient (25 min, 5–35% CH₃CN/0.1% formic acid) at a flow rate of 300 nl/min. The resulting MS and MS-MS data were searched against the Swiss-Prot database using MASCOT software (Matrix Science, London, UK).

**Immunofluorescence Staining**—For histochemical analysis, VATs were fixed with paraformaldehyde, paraffin-embedded, sectioned at a thickness of 5 μm, and stained with biotinylated SSA lectin or DAPI. Briefly, VAT sections were incubated with 0.3% hydrogen peroxide in methanol and treated with the blocking solutions supplied in a tyramide signal amplification kit (TSA Biotin System, PerkinElmer Life Sciences), followed by incubation with biotinylated SSA lectin (overnight at 4 °C) and Alexa 488-labeled streptavidin (30 min at room temperature). DAPI was used for counterstaining. Fluorescence was visualized using an Olympus FV-1000 confocal microscope, and data acquisition and quantification of intensities were carried out using FV10-ASW ver.1.7 software (Olympus).

**Author Contributions**—T. K. and Y. K. conceived the idea for the project. T. K., Y. K., and S. K. designed the experiments. T. K. conducted most of the experiments, prepared figures, and wrote a draft manuscript. T. K., Y. K., S. K., and N. T. revised the paper. All authors interpreted the results, commented on the manuscript, and approved submission of the manuscript.
Acknowledgments—We thank Dr. Yuriko Tachida, Rie Imamaki, Reiko Fujinawa, Ritsuko Oka, Keiko Sato, and Kanoko Sakuda (RIKEN GRC) for technical help. We thank the Support Unit for Bio-Material Analysis, RIKEN BSI Research Resources Center, for technical help with LC/MS-MS analysis. We also thank Dr. Jamey D. Marth for providing the St6gal1 knockout mice and Dr. Ryoji Nagai for technical advice regarding 3T3-L1 cell culture.

References

1. Rosen, E. D., and Spiegelman, B. M. (2006) Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444, 847–853
2. Matsuzawa, Y., Funahashi, T., and Nakamura, T. (1999) Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann. N.Y. Acad. Sci. 892, 146–154
3. Berg, A. H., Combs, T. P., and Scherer, P. E. (2002) ACRF30/ adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 13, 84–89
4. Ouchi, N., Kihsara, S., Arita, Y., Maeda, K., Kuriyama, H., Okamoto, Y., Hotta, K., Nishida, M., Takahashi, M., Nakamura, T., Yamashita, S., Funahashi, T., and Matsuzawa, Y. (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100, 2473–2476
5. Mito, N., Yoshino, H., Hosoda, T., and Sato, K. (2004) Analysis of the effect of leptin on immune function in vivo using diet-induced obese mice. J. Endocrinol. 180, 167–173
6. Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., and Klein, S. (2007) Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56, 1010–1013
7. Kim, J. Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M. E., Hofmann, S. M., Schraw, T., Durand, J. L., Li, H., Gelil, M. L., Meher, M. F., Hui, D. Y., Deshaies, Y., Shulman, G. I., et al. (2007) Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117, 2621–2637
8. Lissner, L., and Heitmann, B. L. (1995) Dietary fat and obesity: evidence from epidemiology. Eur. J. Clin. Nutr. 49, 79–90
9. Lin, S., Thomas, T. C., Storljen, L. H., and Huang, X. F. (2000) Development of high-fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int. J. Obes. Relat. Metab. Disord. 24, 639–646
10. Shimomura, I., Funahashi, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., Yamashita, S., Miura, M., Fukuda, Y., Takemura, K., Tokunaga, K., and Matsuzawa, Y. (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med. 2, 800–803
11. Patrick, C. W., Jr., and Wu, X. (2003) Integrin-mediated adipocyte adhesion and migration on laminin-1. Annu. Biomed. Eng. 31, 505–514
12. Kawaguchi, N., Sundberg, C., Kveiborg, M., Moghadaszadeh, B., Asmar, M., Dietrich, N., Thodeti, C. K., Nielsen, F. C., Möller, P., Mercurio, A. M., Albrechtsen, R., and Wewer, U. M. (2003) ADAM12 induces actin cytoskeletal and extracellular matrix reorganization during early adipocyte differentiation by regulating β1 integrin function. J. Cell Biol. 161, 3893–3904
13. Moremen, K. W., Tiemeyer, M., and Nairn, A. C. (2000) CCAAT enhancer-like protein regulates glucose and lipid metabolism in both adipose tissue and liver. J. Biol. Chem. 275, 4484–4492
14. Ohtsubo, K., Sato, T., Saito, K., Kobayashi, M., and Marth, J. D. (2011) Pathway to adipose tissue from epididymal white adipose tissue: role during adipocyte differentiation. J. Biol. Chem. 284, 19248–19254
15. Nairn, A. C., Berenguer, M., Le Marchand-Brustel, Y., and Govers, R. (2012) Deciphering the role of GLUT4-N-glycosylation in adipocyte and muscle cell models. Biochem. J. 445, 265–273
16. Vosseller, K., Wells, L., Lane, M. D., and Hart, G. W. (2002) Elevation of nuclear-cytosol glucose by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. U.S.A. 99, 5313–5318
17. Haga, Y., Ishii, K., and Suzuki, T. (2011) N-glycosylation is critical for the stability and intracellular trafficking of glucose transporter GLUT4. J. Biol. Chem. 286, 31320–31327
18. Yamauchi, T., Kamo, J., Waki, H., Terauchi, Y., Kubota, N., Harai, H., Morii, Y., Ide, T., Murakami, K., Tsuoyama-Kasaoka, N., Ezaki, O., Akano, Y., Gavrilova, O., Vinson, C., Reitman, M. L., et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipidatrophy and obesity. Nat. Med. 7, 941–946
19. Mito, N., Hosoda, T., Kato, C., and Sato, K. (2000) Change of cytokine balance in diet-induced obese mice. Metabolism 49, 1295–1300
20. Nairn, A. C., York, W. S., Harris, K., Hall, E. M., Pierce, J. M., and Moremen, K. W. (2008) Regulation of glycogen structures in animal tissues: transcript profiling of glycogen-related genes. J. Biol. Chem. 283, 17298–17313
21. Shibuya, N., Takai, K., Song, Z. W., Tarr, G. E., Goldstein, I. J., and Peumans, W. J. (1989) A comparative study of bark lectins from three elderberry (Sambucus) species. J. Biochem. 106, 1098–1103
22. Hoffmann, L. S., Etzrodt, J., Willkomm, L., Sanyal, A., Scheja, L., Fischer, A. W., Stach, J.-P., Bloch, W., Friebe, A., Heeren, J., and Pfeifer, A. (2015) Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue. Nat. Commun. 6, 7235
23. Geurts, L., Everard, A., Van Hul, M., Essaghir, A., Duparc, T., Matamoros, S., Plover, H., Castel, I., Denis, R. G., Bergiers, M., Druart, C., Alhouayek, M., Delzenne, N. M., Muccioi, G. D., Deumoulin, J. B., et al. (2005) Adipose tissue NAP-63-LPL controls fat mass development by altering the browning process and gut microbiota. Nat. Commun. 6, 6495
24. Vosseller, B. M., and Ginty, C. A. (1983) Fibronectin modulation of cell shape and lipogenic gene expression in 3T3-adipocytes. Cell 35, 657–666
25. Wang, Y., Zhao, L., Smas, C., and Sul, H. S. (2010) Pref-1 interacts with fibronectin to inhibit adipocyte differentiation. Mol. Cell Biol. 30, 3480–3492
26. Liu, J., DeYoung, S. M., Zhang, M., Zhang, M., Cheng, A., and Saltiel, A. R. (2005) Changes in integrin expression during adipocyte differentiation. Cell Metab. 2, 165–177
27. Lin, T. H., Aplin, A. E., Shen, Y., Chen, Q., Schaller, M., Romer, L., Aukhil, L., and Juliano, R. L. (1997) Integrin-mediated activation of MAP kinase is
Suppression of Adipogenesis by α2,6-Sialylation

independent of FAK: evidence for dual integrin signaling pathways in fibroblasts. J. Cell Biol. 136, 1385–1395
37. Martin, K. H., Slack, J. K., Boerner, S. A., Martin, C. C., and Parsons, J. T. (2002) Integrin connections map: to infinity and beyond. Science 296, 1652–1653
38. Farmer, S. R. (2006) Transcriptional control of adipocyte formation. Cell Metab. 4, 263–273
39. Rosen, E. D., and Spiegelman, B. M. (2000) Molecular regulation of adipogenesis. Annu. Rev. Cell Dev. Biol. 16, 145–171
40. Londoño Gentile, T., Lu, C., Lodato, P. M., Tse, S., Olejniczak, S. H., Witze, E. S., Thompson, C. B., and Wellen, K. E. (2013) DNMT1 is regulated by ATP-citrate lyase and maintains methylation patterns during adipocyte differentiation. Mol. Cell. Biol. 33, 3864–3878
41. Boqué, N., de la Iglesia, R., de la Garza, A. L., Milagro, F. I., Olivares, M., Bahuelos, O., Soria, A. C., Rodríguez-Sánchez, S., Martínez, J. A., and Campión, J. (2013) Prevention of diet-induced obesity by apple polyphenols in Wistar rats through regulation of adipocyte gene expression and DNA methylation patterns. Mol. Nutr. Food Res. 57, 1473–1478
42. Farner, C., Krief, S., Blache, M., Diot-Dupuy, F., Mory, G., Ferre, P., and Bazin, R. (2003) Adipocyte functions are modulated by cell size change: potential involvement of an integrin/ERK signalling pathway. Int. J. Obes. Relat. Metab. Disord. 27, 1178–1186
43. Whitfield, M. L., George, L. K., Grant, G. D., and Perou, C. M. (2006) Common markers of proliferation. Nat. Rev. Cancer 6, 99–106
44. Semel, A. C., Seales, E. C., Singhal, A., Eklund, E. A., Colley, K. J., and Bellis, S. L. (2002) Hyposialylation of integrins stimulates the activity of myeloid fibronection receptors. J. Biol. Chem. 277, 32830–32836
45. Seales, E. C., Shaikh, F. M., Woodard-Grice, A. V., Aggarwal, P., McBrayer, A. C., Hennessey, K. M., and Bellis, S. L. (2005) A protein kinase C/Ras/ERK signaling pathway activates myeloid fibronection receptors by altering beta1 integrin sialylation. J. Biol. Chem. 280, 37610–37615
46. Isaji, T., Im, S., Gu, W., Wang, Y., Hang, Q., Lu, J., Fukuda, T., Hashii, N., Takakura, D., Kawasaki, N., Miyoishi, H., and Gu, J. (2014) An oncogenic protein Golgi phosphoprotein 3 up-regulates cell migration via sialylation. J. Biol. Chem. 289, 20694–20705
47. Woodard-Grice, A. V., McBrayer, A. C., Wakefield, J. K., Zhuo, Y., and Bellis, S. L. (2008) Proteolytic shedding of ST6Gal-I by BACE1 regulates the glycosylation and function of a4β1 integrins. J. Biol. Chem. 283, 26364–26373
48. Lu, J., Isaji, T., Im, S., Fukuda, T., Kameyama, A., and Gu, J. (2016) Expression of N-acetylgalactosaminyltransferase III suppresses α2,3 sialylation, and its distinctive functions in cell migration are attributed to α2,6-sialylation levels. J. Biol. Chem. 291, 5708–5720
49. Hedlund, M., Ng, E., Varki, A., and Varki, N. M. (2008) α2–6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res. 68, 388–394
50. Lu, J., and Gu, J. (2015) Significance of β-galactoside α2,6 sialyltransferase 1 in cancers. Molecules 20, 7509–7527
51. Fuentes, P., Acuña, M. J., Cifuentes, M., and Rojas, C. V. (2010) The anti-adiagenic effect of angiotensin II on human preadipose cells involves ERK1,2 activation and PPARγ phosphorylation. J. Endocrinol. 206, 75–83
52. Scott, R. E., Florine, D. L., Wille, J. J., Jr, and Yun, K. (1982) Coupling of growth arrest and differentiation at a distinct state in the G1 phase of the cell cycle. GD. Proc. Natl. Acad. Sci. U.S.A. 79, 845–849
53. Zhang, J. W., Tang, Q. Q., Vinson, C., and Lane, M. D. (2004) Dominant-negative C/EBP disrupts mitotic clonal expansion and differentiation of 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci. U.S.A. 101, 43–47
54. Lauc, G., Voija, A., and Zoldos, V. (2014) Epigenetic regulation of glyco-sylation is the quantum mechanics of biology. Biochim. Biophys. Acta 1840, 65–70
55. Kizuka, Y., Kitazume, S., Okahara, K., Villagra, A., Sotomayor, E. M., and Taniguchi, N. (2014) Epigenetic regulation of a brain-specific glycosyltransferase N-acetylgalactosaminyltransferase-IX (GnT-IX) by specific chromatin modifiers. J. Biol. Chem. 289, 11253–11261
56. Kawamura, Y. I., Toyota, M., Kawashima, R., Hagiwara, T., Suzuki, H., Imai, K., Shimomura, Y., Tokino, T., Kannagi, R., and Dohi, T. (2008) DNA hypermethylation contributes to incomplete synthesis of carb-hydrate determinants in gastrointestinal cancer. Gastroenterology 135, 142–151.e3
57. Kizuka, Y., and Taniguchi, N. (2016) Enzymes for N-glycan branching and their genetic and nongenetic regulation in cancer. Biomolecules 6, 25
58. Antony, P., Rose, M., Heidenreich, A., Knüchel, R., Gaisa, N. T., and Dahl, E. (2014) Epigenetic inactivation of ST6GAL1 in human bladder cancer. BMC Cancer 14, 901
59. Minami, A., Shimon, Y., Mizutani, K., Nobutani, K., Momose, K., Azuma, T., and Takai, Y. (2013) Reduction of the ST6 β-galactosamidase α-2,6-sialyltransferase 1 (ST6GAL1)-catalyzed sialylation of nectin-like molecule 2/cell adhesion molecule 1 and enhancement of ErbB2/ErbB3 signaling by microRNA-199a. J. Biol. Chem. 288, 11845–11853
60. Kroes, R. A., and Moskal, J. R. (2016) The role of DNA methylation in ST6GAL1 expression in gliomas. Glycobiology 26, 1271–1283
61. Hennet, T., Chui, D., Paulson, J. C., and Marth, J. D. (1998) Immune regulation by the ST6GAL1 sialyltransferase. Proc. Natl. Acad. Sci. U.S.A. 95, 4504–4509
62. Marino, J. H., Tan, C., Davis, B., Han, E. S., Hickey, M., Naukam, R., Taylor, A., Miller, K. S., Van De Wiele, C. J., and Teague, T. K. (2008) Disruption of thymopoiesis in ST6Gal1-deficient mice. Glycobiology 18, 719–726
63. Kitazume, S., Imamaki, R., Ogawa, K., Komi, Y., Futakawa, S., Kojima, S., Hashimoto, Y., Marth, J. D., Paulson, J. C., and Taniguchi, N. (2010) α2,6-sialic acid on platelet endothelial cell adhesion molecule (PECAM) regulates its homophilic interactions and downstream antiapoptotic signaling. J. Biol. Chem. 285, 6515–6521
64. Shabana Ulah Shahid, S., Wah Li, K., Acharya, J., Cooper, J. A., Hasnain, S., and Humphries, S. E. (2016) Effect of six type II diabetes susceptibility loci and an FTO variant on obesity in Pakistani subjects. Eur. J. Hum. Genet. 24, 903–910
65. Kooner, J. S., Saleehen, D., Sim, X., Sehni, J., Zhang, W., Frossard, P., Been, L. F., Chia, K. S., Dimas, A. S., Hassanali, N., Jafar, T., Jowett, J. B., Li, X., Radha, V., Rees, S. D., et al. (2011) Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat. Genet. 43, 984–989
66. Kitazume, S., Oka, R., Ogawa, K., Futakawa, S., Hagiwara, Y., Takikawa, H., Kato, M., Kasahara, A., Miyoishi, E., Taniguchi, N., and Hashimoto, Y. (2009) Molecular insights into β-galactoside α2,6-sialyltransferase secretion in vivo. Glycobiology 19, 479–487
67. Kizuka, Y., Nakano, M., Miura, Y., and Taniguchi, N. (2016) Epigenetic regulation of neural N-glycans. Proteomics 16, 2854–2863
68. Ahmed, S. A., Gogal, R. M., Jr, and Walsh, J. E. (1994) A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J. Immunol. Methods 170, 211–224